TREVOR HALLAM, Ph.D.

Trevor J. Hallam, Ph.D., is currently CSO of Laronde, a private biotech company designing and developing a new class of translatable circular “endless” RNA modalities that are capable of addressing a wide range of therapeutic needs that have been underserved by the limitations of current drug design.  Dr Hallam served as Sutro’s Chief Scientific Officer from December 2010 to May 2023, where he led the strategic focus of the company’s technology development into precision design of complex conjugated biologics. During his tenure 6 novel therapeutics progressed into clinical development.  He was promoted to President, Research and CSO in 2021. Prior to joining us, Dr. Hallam was Executive Vice President of Research & Development at Palatin Technologies, Inc., and held several senior management positions in various pharmaceutical companies, including AstraZeneca PLC, Roche, Glaxo and SmithKline & French.  Dr. Hallam received a BSc (Hons) in Biochemistry from the University of Leeds and a Ph.D. in Biochemistry from Kings College, University of London. He then conducted post-doctoral training at the Physiological Laboratory, University of Cambridge with Dr Tim Rink.